Key facts
- This page summarizes Amy E. Tapper's Form 4 filing for Imago BioSciences, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 21 Jul 2022, 17:49.
Amy E. Tapper - 20 Jul 2022 Form 4 Insider Report for Imago BioSciences, Inc.
- Reporting relationship
- Senior Vice President, Non-Clinical and CMC
- Issuer ticker
- N/A
- Reported as of
- 20 Jul 2022
- Net transaction value
- -$11,535
- SEC form
- 4
- Accepted by SEC
- 21 Jul 2022, 17:49:42 UTC
- Prior SEC filing
- 15 Feb 2022
- Next SEC filing
- 16 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Hugh Rienhoff, as Attorney-in-fact for Amy Tapper
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Amy E. Tapper filed Form 4 for Imago BioSciences, Inc. on 21 Jul 2022.
Change
- Previous filing in this sequence was filed on 15 Feb 2022.
- Current net transaction value: -$11,535.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMGO
transaction
Common Stock
Options Exercise
- Transaction value
- $1,890
- Shares
- +750
- Change %
- +0.63%
- Price
- $2.52*
- Shares after
- 119,797
- Date
- 20 Jul 2022
- Ownership
- Direct
- Footnotes
- F1
IMGO
transaction
Common Stock
Sale
- Transaction value
- $13,425
- Shares
- -750
- Change %
- -0.63%
- Price
- $17.90
- Shares after
- 119,047
- Date
- 20 Jul 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMGO
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -750
- Change %
- -1.1%
- Price
- $0.000000
- Shares after
- 64,982
- Date
- 20 Jul 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 750
- Exercise price
- $2.52
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
SEC remarks
Senior Vice President, Non-Clinical and CMC